Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05633160 · ClinicalTrials.gov registry record · Phase 1
64Cu-SAR-BBN and 67CU SAR-BBN for Identification and Treatment of Gastrin Releasing Peptide Receptor (GRPR)-Expressing Metastatic Castrate Resistant Prostate Cancer in Patients Who Are Ineligible for Therapy With 177Lu-PSMA-617 (COMBAT)
A Phase 1 study, sponsored by Clarity Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT05633160 is a Phase 1 study that was terminated before completion, run by Clarity Pharmaceuticals. The registered enrollment target is 4 participants.
The verdict
NCT05633160, a Phase 1 study, was terminated before completion, sponsored by Clarity Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
The aim for this study is to determine the safety and efficacy of 67Cu-SAR-BBN in participants with Gastrin Releasing Peptide Receptor (GRPR)-expressing metastatic castrate resistant prostate cancer in patients who are ineligible for therapy with 177Lu-PSMA-617.
Interventions
- DRUG 64Cu-SAR-BBN
- DRUG 67Cu-SAR-BBN
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2023-06-15 |
| Est. Completion | 2025-04-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05633160
The ClinicalTrials.gov registry entry for NCT05633160 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Clarity Pharmaceuticals, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which 64Cu-SAR-BBN is the first listed.
NCT05633160 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05633160 about?
NCT05633160 is a clinical study titled "64Cu-SAR-BBN and 67CU SAR-BBN for Identification and Treatment of Gastrin Releasing Peptide Receptor (GRPR)-Expressing Metastatic Castrate Resistant Prostate Cancer in Patients Who Are Ineligible for Therapy With 177Lu-PSMA-617 (COMBAT)". The aim for this study is to determine the safety and efficacy of 67Cu-SAR-BBN in participants with Gastrin Releasing Peptide Receptor (GRPR)-expressing metastatic castrate resistant prostate cancer in patients who are ineligible for therapy with 177Lu-PSMA-617.
What is the current status of trial NCT05633160?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2023-06-15. Estimated completion is 2025-04-23.
What interventions are being tested in trial NCT05633160?
The interventions under investigation include: 64Cu-SAR-BBN (DRUG), 67Cu-SAR-BBN (DRUG).
Who is sponsoring clinical trial NCT05633160?
This trial is sponsored by Clarity Pharmaceuticals, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.